Finance

Beta
Lists
CNXU:NASDAQ
Conexeu Sciences Inc
$9.82
-13.02%
(-1.47) 1D
Jun 15, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CNXU...
Open
$11.05
High
$11.50
Low
$9.66
Mkt. cap
262.77M
Avg. vol.
49.86K
Volume
90.83K
52-wk high
$18.79
52-wk low
$9.66
EPS
-$0.26
Open
$11.05
High
$11.50
Low
$9.66
Mkt. cap
262.77M
Avg. vol.
49.86K
Volume
90.83K
52-wk high
$18.79
52-wk low
$9.66
EPS
-$0.26
News stories
From sources across the web
About Conexeu Sciences Inc
CEO-
Employees-
Founded2022
HeadquartersReno, Nevada, United States
SectorBiotechnology
Websiteconexeu.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Oct 2024
Jan 2025
Oct 2025
Jan 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
198.73K
23.67K
71.90K
62.56K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.10K
308.49K
2.21M
1.64M
Operating expense
225.83K
332.72K
1.90M
1.71M
Total operating expenses
225.83K
332.72K
1.90M
1.71M
Operating income
-225.83K
-332.72K
-1.90M
-1.71M
Other non operating income
-340.00
-732.00
28.10K
-10.71K
EBT including unusual items
-109.10K
-290.06K
-1.88M
-1.72M
EBT excluding unusual items
-228.83K
-333.24K
-1.88M
-1.72M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-109.10K
-290.06K
-1.88M
-1.72M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
1.34K
11.29K
Interest expense
-3.91K
-3.61K
-
-
Net interest expenses
-3.91K
-3.61K
1.34K
11.29K
Depreciation and amortization charges
-
563.00
6.65K
6.44K
EBITDA
-
-332.16K
-1.90M
-1.71M
Gain or loss from assets sale
-
-
-
2.74K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer